Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.